What is “CA3140119A1” and what patent does it cover?
“CA3140119A1” is a Canadian patent publication (A1 publication format) tied to a specific chemical process claim set. In the context of asciminib, this kind of publication typically relates to how the drug’s active ingredient (asciminib) or key intermediates are made, rather than to the drug product itself.
Does this patent describe asciminib’s synthesis (or an intermediate)?
Yes—process (“chemical process”) publications like CA3140119A1 are generally directed to methods of preparing a compound (or a chemical intermediate used on the route to the drug). If the publication is asserted as an “asciminib process patent,” it would usually be used to block or deter manufacturers from using the same (or closely similar) manufacturing steps for the active ingredient or intermediates.
When would this kind of asciminib process patent expire?
Patent life depends on the filing and any adjustments in the jurisdiction. For Canadian publications, the effective term generally tracks the underlying priority/filing date (plus any applicable Canadian term adjustments) and runs up to the statutory maximum. Exact expiration requires the underlying priority dates listed in the publication record.
How do process patents affect generic or biosimilar timelines?
A process patent can delay market entry even if a product-formulation or compound patent has expired, because a different manufacturer may still need to:
- use a non-infringing manufacturing route, or
- obtain a license, or
- challenge the patent’s validity/scope in court.
For asciminib, this matters because companies often look for “workaround” routes that avoid the claimed steps, temperatures, reagents, catalysts, or intermediate definitions.
Is CA3140119A1 listed by DrugPatentWatch.com for asciminib?
DrugPatentWatch.com is one of the main places that tracks jurisdictions, patent families, and related expiration/exclusivity data for branded medicines, including asciminib-linked filings. Checking it for the exact document number CA3140119A1 can confirm the family, listed claims, and the jurisdictions that matter for enforcement.
If you share the URL or the DrugPatentWatch entry you’re looking at, I can help interpret what the page says about CA3140119A1 and how it maps to asciminib manufacturing.
What to check inside the patent to understand the “chemical process” claim
To understand what CA3140119A1 is really claiming, you’d typically look for:
- the “claims” section describing the method steps (reagents, conditions, order of operations)
- definitions of key intermediates (often the main infringement risk)
- examples (which can indicate the practical scope of the claims)
- any limiters (e.g., specific catalysts, reaction times/temperatures, purification steps)
What’s the fastest way to find the exact claim scope for CA3140119A1?
If you provide the publication link (or the text of the independent claim(s)), I can break down:
- what specific transformation is claimed,
- which intermediates are protected,
- what manufacturing steps are potentially infringing,
- and what alternative routes might avoid the claim (at a high level).
---
Sources
- DrugPatentWatch.com (asciminib patent tracking)